KR20050021590A - Composition comprising crude drug complex for treatment and prevention of liver disease - Google Patents

Abstract

PURPOSE: A composition for treatment and prevention of liver disease comprising crude drug complex is provided, which composition has improved antiviral activity, in particular against hepatitis B virus(HBV), so that it can be useful for treatment and prevention of liver disease caused by HBV. CONSTITUTION: The composition for treatment and prevention of liver disease comprises alum or ammonium aluminum sulfate and mustard(Brassica juncea), wherein alum, ammonium aluminum sulfate and mustard(Brassica juncea) is purchasable or processed; the liver disease is hepatitis, liver cirrhosis or liver cancer caused by hepatitis B virus. The composition for treatment and prevention of liver disease comprises 0.01 to 80 wt.% of the crude drug complex. A health food comprises alum or ammonium aluminum sulfate and mustard(Brassica juncea).

Description

Composition comprising crude drug complex for treatment and prevention of liver disease

The present invention relates to a composition for treating and preventing liver disease, which contains the complex herbal composition.

As modern medicine advances, bacterial diseases are markedly suppressed by the development of antibiotics and preventive vaccines, but viral diseases are not yet conquered, but rather are reported to increase through air pollution and environmental pollution. However, only a few viral diseases in which prophylactic vaccines are developed, and fundamental treatments for many diseases, including viral flu, hepatitis, aseptic meningitis, and the like, have not yet been developed.

Hepatitis B virus (hereinafter referred to as HBV virus) belongs to the family of hepadnaviruses and is a non-cytopathic DNA virus that causes acute hepatitis as well as chronic liver disease including cirrhosis and liver cancer. The gene maintains a relaxed circle with an incomplete double helix structure of about 3,200 bp (Peutherer JF. Hepadnaviruses. In: Greenwood D, Slack RCB, Peutherer JF. Medical Microbiology 14th ed. Edinburgh: Churchill Livingstone, 1994; 527-540).

Self-replicating of HBV virus begins with the attachment of virions to hepatocytes. Once the synthesis of the plus strand of HBV viral DNA is completed in the nucleus of the hepatocytes, the viral gene is covalently closed. circular DNA, cccDNA). This cccDNA becomes a template of pregenomic RNA, which is then reverse transcribed into the minus strand of HBV viral DNA. This cccDNA has two origins: either a new virus particle has entered the hepatocytes, or a partially double stranded DNA that was in the immature nucleocapsid in the cytoplasm. to be. Most antiviral agents are known to have little effect on this cccDNA (Locarnini S, Birch C., J Hepatol 30: 536-550, 1999). This is because serum HBV virus is quickly resolved when treatment with antiviral agents is discontinued. It is thought to be the reason for the appearance of DNA.

The pathogenesis of chronic hepatitis B has not been elucidated, but the decisive factor is presumably due to the impairment of the immune response, which continues the proliferation of the virus and the immune system's response to incomplete control. Under these theoretical backgrounds, many studies and attempts have been made on drugs that enhance immunity and antiviral agents that can directly inhibit the proliferation of viruses for the treatment of chronic hepatitis B. The purpose of chronic hepatitis B treatment is to inhibit self-replicated HBV virus and maintain remission of hepatitis. Currently, interferon (IFNs) and lamivudine are mainly used to treat chronic hepatitis B. Interferon has antiviral effects, proliferation suppression, and immunomodulatory functions. In particular, IFN-α is known to be very effective in inhibiting HBV virus self-replicating and inducing remission of liver disease. However, there is a limit that the efficacy of IFN-α is limited to only a few patients who are well selected. It is also known to be less effective in Asian patients, which are expensive and have many side effects, and infections that begin shortly after birth are problematic (Wong DK, et al., Ann. Intern. Med., 119: 312-323, 1993).

Hepatitis B is important to treat, but more importantly, to prevent the involvement of the hepatitis B virus in the conversion to incurable liver cancer. Most of the HBV virus growth occurs in the liver, but some occur in the spleen, kidney, pancreas, bone marrow, and the like. However, proliferation in these organs other than liver does not cause tissue damage, only HBV virus.

As such, chronic hepatitis B is characterized by systemic diseases, has a very complex and complex pathogenesis, and ultimately, disorders of the immune system become important causes. However, laboratory methods for the immunological pathophysiology of HBV virus have not been fully developed compared to other research fields. Thus, the pathophysiological mechanisms of hepatitis B are still far from established. There are also few treatments that can help those who are infected.

Alumen is a crystal of refined alum and bauxite. The surface is colorless or white, soluble in water, insoluble in ethanol, and main component is alum (KAl (SO ₄ ) ₂ 12H ₂ O). It is known to have the effects of hemostasis, branch and expectoration since ancient times.

White egg (Sinapsis Alba Semen) is a ripe seed of mustard ( Brassica juncea Cosson), and it is yellowish brown to pale yellow powder. Sinalbin, sinapine, sinigrin, and fatty oils are known to have expectoration and skin irritation. (People of Korean Medicine Standards, KPJ, Sang-Joon Lee, I, Korea Medical Index, p453-454, 1988: Jung-Seop Shin, Min-Kyo Shin, Younglim, Dohae Hyangdae, p572-573, 1998).

Therefore, the present inventors studied anti-HBV virus components using various kinds of mineral herbals and plant herbs present in nature, and confirmed that the composite herbal composition containing alum and petroleum sulfur exhibited excellent HBV virus growth inhibition effect. In order to provide a composition for treating a new liver disease, the present invention was completed.

It is an object of the present invention to provide a composition containing a combination drug having antiviral activity.

In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing and treating liver disease containing alum or ammonium aluminum sulfate and white egg or individual.

Such liver diseases include diseases caused by hepatitis B virus, liver diseases such as hepatitis, cirrhosis and liver cancer.

Such alum or ammonium aluminum sulfate and white egg or individual include those that are commercially available and those processed or specially treated according to their use.

Alumina and white dog are usually ingested as it is raw material can cause some side effects and only a small amount can be ingested, so it is desirable to perform the appropriate processing.

The alum of the present invention may be used to obtain a specially processed high alum by repeating a high temperature heating and solidification process several times, and may use it by powdering it.

In addition, the white egg of the present invention can be used as a raw material obtained through the following processing.

For example, the white can be used in the present invention, by immersing the commercially available white 100 in water, and immersed for 3 to 7 days while exchanging water once or twice a day and then drying it Can be obtained.

In the process, the water uses distilled water or purified water, and the immersion period may be changed according to the climate or the external environment, and about 1 to 10% by weight of additional herbal medicine, which is not cold during the immersion process, preferably Can be added in a mixing ratio of about 5% by weight.

However, because of the strong nature of the white dog, it is difficult for adults to consume 100mg per day, so in order to use it as a medicine or food, it should be used together with other medicines that can control the toxicity and side effects. After about 10 days, the processed white dog of the present invention can be obtained.

The alum and white powder obtained in this way are mixed in a ratio of 1 to 10: 1, preferably 1 to 3: 1, and mixed with flour or wheat flour dough, depending on the characteristics of the injector, respectively. Various conventional types of materials can be obtained.

The composition containing alum and algae as an active ingredient obtained by the above production method is excellent in inhibiting the proliferation of hepatitis B virus as compared with the conventional hepatitis B treatment.

The composition having the antiviral activity provides a pharmaceutical composition having 0.01 to 80%, preferably 1 to 50% by weight of the multi-drug, based on the total weight of the total composition.

In addition, the composition having the antiviral activity can be used for the treatment of liver diseases such as hepatitis, cirrhosis and liver cancer.

Compositions comprising the multi-drug of the invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.

Carriers, excipients and diluents that may be included in the composition comprising the complex herbal of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, Calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

Formulations of the composition having an antiviral activity comprising the complex herbal of the present invention may be used as warning agents, granules, lotions, liniments, limonades, fragrances, powders, syrups, ointments, liquids. , Extractant, elixier, ointment, lactose, liquid extract, emulsion, suspension, eye drops, tablets, suppositories, injections, spirits, dips, premises, pasta, cataplasmase ( cataplasma, capsules, troches, tinctures or pills are preferred, but are not limited to the above formulations, and are formulated in the form of oral dosage forms, external preparations, suppositories, and sterile injectable solutions. Can be used.

The composition containing a permanent herbal medicine of the present invention can be parenterally administered or orally administered according to the desired method, and the amount of 0.001 to 10 g, preferably 0.01 to 5 g per 1 kg of body weight as an active ingredient per day 1 to several times You can drink it by dividing it into. Drinking dose level for a particular person may vary depending on the person's weight, age, sex, health status, diet, drinking method, excretion rate, the severity of symptoms, the drinking dose limits the scope of the invention in any aspect It is not.

In addition, the present invention provides a health functional food comprising a compound herbal powder exhibiting antiviral activity and a food supplement acceptable food supplement.

The combination herbal of the present invention may be added to food or beverage for the purpose of preventing liver disease. At this time, the amount of the combined herbal in food or beverage, in general, the functional food composition of the present invention can be added to 0.01 to 15% by weight of the total food weight, the health beverage composition is 0.01 to 10 g based on 100 ml Preferably, it can be added in the ratio of 0.1-1 g.

The health beverage composition of the present invention has no particular limitation on the liquid component except for containing the compound herbal as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates, etc. as additional ingredients, as in general beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. The compositions of the present invention may also contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected from the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.

Hereinafter, the present invention will be described in detail by way of examples.

However, the following Examples and Experimental Examples are only illustrative of the present invention, and the content of the present invention is not limited to the following Examples and Experimental Examples.

Example 1 Preparation Example 1 of the composite herbal powder

After 400g of alum was dried in a dryer, it was repeated several times of high temperature heating and solidification. This state was powdered to obtain a specially processed high alum. In addition, the process of exchanging distilled water every day was repeated for 7 days by dipping 200 g of 100 Koreans purchased from Gyeongdong Market. The white dog was dried and then powdered.

400 g of the alum powder, 200 g of white egg and 400 g of wheat flour were mixed uniformly with a mixer, and then, 1000 ml of brine was added thereto, evenly kneaded with a kneader, and dried to obtain 1000 g of a compound herbal powder. When used in the experiment was dissolved in PBS sterilized.

Example 2 Preparation Example 2 of the composite herbal powder

100 g of alum was melted by heating at high temperature, and then solidified, and powdered to obtain a specially processed high alum. In addition, the process of exchanging distilled water every day by immersing 100 g of 100 whites purchased from Gyeongdong market and distilled water was repeated for 3 days, dried and powdered.

100 g of the alum powder and 100 g of white sugar were mixed uniformly with a mixer, and then, 100 ml of brine was added thereto, and then uniformly kneaded with a kneader, and dried to obtain 200 g of a compound herbal powder. When used in the experiment was dissolved in PBS sterilized.

Experimental Example 1. HBV virus DNA inhibition experiment

In order to measure the inhibitory ability of HBV virus against DNA of the powders of Examples 1 and 2 of the present invention, the DNA of hepatitis B virus present in serum was quantitated by chemiluminescence on a microplate.

The experiment was performed by using RNA probes (RNA probes, ad & av stralms) capable of binding to DNA of the HBV virus contained in the serum, and then making a DNA: RNA hybrid to a microplate containing specific antibodies thereto. After capturing and binding the captured hybrid to an antibody conjugated with alkaline phosphatase, the chemiluminescent material is used to measure the amount of DNA of the HBV virus present in the serum by light intensity and the standard curve ( As a method of determining the concentration through a calibration curve, a hybrid capture II HBV DNA test kit (manufactured by Digene) was used for the experiment.

The experiment was performed with sera from 11 patients with type B infection, HBV virus (National Institute of Gastrointestinal Tract Virus, October 18, 2002) DNA and active virus in the sera of patients with active viral type B infection. Serum HBV virus DNA (Sample Group A) was treated with a mixture of alum and a white egg mixture (50 µg / ml) of Example 1, diluted with PBS solution, for 2 hours and 8 hours at 37 ° C. ) Was compared to determine the HBV virus DNA inhibitory effect of the combined drug of the present invention.

1-1. Control and experimental groups

Calibrator 1 (Cal 1) is the carrier DNA and sodium azide in HBV negative human serum, Calibrator 2 (Cal 2) is 1.42 × 10 ⁵ copies / ml ( ⁵ pg / ml) in HBV negative human serum. HBV virus plasmid DNA with carrier DNA and sodium azide, Calibrator 3 (Cal 3) is 2.83 × 10 ⁷ copies / ml (100 pg / ml) HBV virus plasmid DNA with HBV negative human serum and carrier DNA and sodium azide. Zide, Calibrator 4 (Cal 4), contains 5.66 × 10 ⁸ copies / ml (2000 pg / ml) HBV virus plasmid DNA and carrier DNA and sodium azide in HBV-negative human serum. ) Contains 1.70 × 10 ⁹ copies / ml (6000 pg / ml) HBV virus plasmid DNA in HBV negative human serum and carrier DNA and sodium azide.

As a negative control group, the C2 group was mixed with PBS for hepatitis serum containing HBV and left at 37 ° C. for 2 hours, and the C4 group was left for 8 hours.

As a positive control group, Z2 group was mixed with HBV-containing hepatitis serum and zepix (ramimidine 1mg / ml) and left at 37 ° C for 2 hours, and Z4 group was left for 8 hours.

Experimental group S was treated with 10 µl of PBS in 20 µl of active viral type B infected patients, and experimental group A was treated with 20 µl of active viral type B infected patients with a mixed herbal solution of Experimental Example 2 (concentration: 50 g / 1.5 l). ) 10 μl.

1-2. Combined Herbal Treatment of Serum with HBV

First remove the microplate from the microplate heater, which was previously set at 65 ° C, then immediately remove the sealer, vortex the sample for 10-15 seconds in advance and avoid contact with the wall during dispensing. Calibrators; 3 each of Cal 1, Cal 2, 2 each of Cal 3, Cal 4 and Cal 5, control group (P ₃ and P ₂ ), experimental group (experimental group S and experimental group) 30 microliters (20 microliters of HBV positive serum and 10 microliters of PBS diluent) were each dispensed by A), and 30 microliters (20 microliters of HBV positive serum and 10 microliters of PBS) were also dispensed.

The microplate was covered using a microplate sealer and incubated at 37 ° C. for 120 minutes.

1-3. Denaturation

One drop of an indicator dye was added to a denaturation reagent bottle, and then 30 μl of a denaturing reagent was dispensed into each well of the microplate of 1-1. The wells were then covered with a sealer and mixed by shaking at 1100 ± 100 rpm for 1 minute. At this time, the solution was changed to purple, and reacted for 30 ± 3 minutes in a heater of 65 ± 2 ℃.

1-4. Probe mixture preparation

After centrifuging the reagent bottle containing the HBV probe in the hybrid capture kit for 3-5 seconds, the probe mixture was prepared by thoroughly mixing 240 µl in 6.0 ml of the diluent of the probe.

1-5. Hybridization

The sealer of the microplate of Experimental Example 1-1 was removed, and 30 µl of the probe mixture of Experimental Example 1-3 was dispensed, and the plate was again covered with a sealer and mixed by shaking at 1100 ± 100 rpm for 1 minute. At this time, the color of the solution was changed to yellow, and reacted again for 30 ± 3 minutes in a heater of 65 ± 2 ℃.

1-6. Hybrid capture reaction

After removing the plates 1-5, the calibrator, the control, and the drug-treated samples were transferred to each well by 75 µl with a capture microplate (DIGENE Co., Ltd.), and the caps were covered with a sealer and 60 at 18 to 25 ° C. The reaction was shaken at 1100 ± 100 rpm for ± 5 minutes. After the reaction, the filtrate of the capture microplate was removed with a pipette and then beaten again on a blotting paper two or three times to completely remove the filtrate.

1-7. Hybrid capture detection

Capture 75 μL of each of the detection reagents (in-kit search reagent 1) reacted with an antibody against an RNA: DNA hybrid conjugated with alkaline phosphatase in a buffer containing sodium azide. The microplate wells were aliquoted, capturing the capture microplate wells using a microplate sealer and incubating for 30 minutes at 20-25 ° C. Thereafter, the filtrate of the capture microplate well was completely removed, and then the capture microplate well was washed six times by overflowing the capping wash with sodium azide and then turning it upside down.

1-8. Signal amplification

The washed capture plate was left inverted for 10-15 minutes on a clean blotter paper to absorb the remaining filtrate, and each capture microplate well was filled with a chemiluminescent material (CDP-Star ^™ , Chemilumlnescent substrate, Search Reagent 2 in the kit). Aliquots were aliquoted. The microplate sealer was used to cover the capture microplate wells and incubated for 15 minutes at room temperature under direct sunlight. Within 15 minutes after the reaction was completed, the amount of DNA of the HBV virus in the serum was measured using a DML 2000 luminometer (Luminometer, DIGENE) as a light intensity.

In the experiments, P ₃ and P ₂ (positive control) included infectious HBV virus and sodium azide.

1-9. result

Group C, a negative control group, was mixed with PBS for hepatitis serum containing HBV and left at 37 ° C. for 2 hours and for 8 hours.

As a positive control group, Z group was mixed with HBV-containing hepatitis serum and zepix (ramimidine 1mg / ml) and left for 2 hours at 37 ° C for 8 hours.

Experimental group S was treated with 10 µl of PBS in 20 µl of active viral type B infected patients, and experimental group A was treated with 20 µl of active viral type B infected patients with a mixed herbal solution of Experimental Example 2 (concentration: 50 g / 1.5 l). 10μl)

Looking at the results of Table 1, it was confirmed that the amount of HBV DNA in the experimental group A treated with the compound herbal was reduced than the experimental groups C and Z to inhibit the HBV virus.

Treatment group HBV DNA Volume (pg / ml) 2 hours reaction 8 hours response A: alum + whites 149.195 105.829 C: PBS treatment 236.134 260.337 Z: lamivudine treatment 232.607 233.199

In addition, the results of Table 2 show that when the composition of the present invention was treated with the sera of 11 patients, the HBV virus DNA was significantly reduced compared to the PBS treatment with 9 sera, and the composition of the present invention was effective in inhibiting HBV virus growth. It was confirmed that there is.

Calibration Experimental Group S Experiment group A Cal No. HBV virus DNA concentration (copies / ml) No. HBV virus DNA concentration (copies / ml) No. HBV virus DNA concentration (copies / ml) Cal 1 72 S1 574 N1 540 Cal 1 70 S2 2458 N2 1408 Cal 1 74 S3 2630 N3 2996 Cal 2 96 S4 5746 N4 5976 Cal 2 78 S5 8374 N5 5428 Cal 2 82 S6 14002 N6 12738 Cal 3 4724 S7 16330 N7 12072 Cal 3 4468 S8 22710 N8 21332 Cal 4 80162 S9 26446 N9 20520 Cal 4 71734 S10 28912 N10 27198 Cal 5 121946 S11 38380 N11 32894 Cal 5 118494 P2 7756 P3 180

Experimental Example 4. Toxicity Test

In order to test the toxicity of the combination herbal of the present invention, animal experiments were performed.

The compound medicine of the present invention was divided into three groups of 25 ± 5g ICR mice (central laboratory animals) and 235 ± 10g SPF Sprague Dawley (Biogenomics) rats, respectively, divided into three groups. Example 1) Toxicity was observed for 24 hours after intraperitoneal administration at doses of 20 mg / kg, 10 mg / kg and 1 mg / kg, respectively.

As a result, no deaths were observed in all three groups, and no significant symptoms were found in weight gain and feed intake. Therefore, the combination herbal of the present invention was confirmed to be a safe drug.

The combination herbal of the present invention can be administered in the following formulations, and the following formulation examples are merely illustrative of the present invention, whereby the content of the present invention is not limited.

Examples of the formulation of the pharmaceutical formulations described below will be described, but this is not intended to limit the present invention but merely to explain in detail.

Formulation Example 1 Preparation of Injection

Combined herbal medicine of Example 1 ... 1.0 mg

Sodium metabisulfite ........ 3.0mg

Methylparaben ............... 0.8 mg

Propylparaben ...................... 0.1 mg

Sterile distilled water for injection ..............

The above ingredients are mixed and made into 2 ml by a conventional method, and then filled into 2 ml ampoules and sterilized to prepare an injection.

Formulation Example 2 Preparation of Tablet

Combination herbal medicine of Example 1 ... 20 mg

Lactose 100 mg

Starch .............................. 100 mg

Magnesium Stearate ...............

The above components are mixed and tableted according to a conventional method for producing tablets to produce tablets.

Formulation Example 3 Preparation of Capsule

Combined herbal medicine of Example 1 ... 10 mg

Lactose 50 mg

Starch ........................................ 50 mg

Talc ........................................ 2mg

Magnesium Stearate ...............

Capsules are prepared by mixing the above ingredients and filling into gelatin capsules according to a conventional method for preparing capsules.

Formulation Example 4 Preparation of Liquid

Combined herbal medicine of Example 1 ... 100 mg

Sugar .................................. 20g

Isomerized sugar ......................................... 20 g

Lemon Flavor ......................

Purified water is added to the whole ........... 100ml

The above components are mixed according to a conventional method for preparing a liquid, filled into a 100 ml brown bottle, and sterilized to prepare a liquid.

Formulation Example 5 Preparation of Healthy Food

Combined herbal medicine of Example 1 ... 1000 mg

Vitamin Blend ........................

Vitamin A Acetate ............... 70 μg

Vitamin E ........... 1.0 mg

Vitamin B1 ......... 0.13 mg

Vitamin B2 ........... 0.15 mg

Vitamin B6 ............ 0.5 mg

Vitamin B12 ........................ 0.2 μg

Vitamin C ......................................... 10 mg

Biotin ............... 10 μg

Nicotinic Acid Amide ... 1.7 mg

Folic acid ............... 50 ㎍

Calcium Pantothenate ..................... 0.5 mg

Inorganic mixtures ...............

Ferrous Sulfate ............... 1.75 mg

Zinc Oxide ........... 0.82 mg

Magnesium Carbonate ......... 25.3 mg

Potassium monophosphate ......................................... 15 mg

Dicalcium Phosphate ............... 55 mg

Potassium citrate ... 90 mg

Calcium Carbonate ... 100 mg

Magnesium Chloride ............... 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method. The granules may be prepared and used for preparing a health food composition according to a conventional method.

Formulation Example 6 Preparation of Healthy Drink

Combined herbal medicine of Example 1 ..................... 1000 mg

Citric Acid ........................................ 1000 mg

Oligosaccharide ......................... 100 g

Plum concentrate ........................... 2 g

Taurine ......................................... 1 g

Purified water is added ............................................. 900 ml

After mixing the above components in accordance with a conventional healthy beverage production method, and stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and then refrigerated and stored in the present invention For the preparation of healthy beverage compositions.

Although the composition ratio is a composition that is relatively suitable for the preferred beverage in a preferred embodiment, the compounding ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.

Complex herbal medicine containing alum and algae provided by the present invention is excellent in inhibiting HBV virus proliferation, and thus can be used in medicines and health functional foods as compositions having therapeutic activity for liver disease.

1 is a graph comparing the amount of HBV DNA in the serum of a hepatitis B patient treated with the compound herbal of the present invention compared to the untreated group.

Claims (5)

A composition for the prevention and treatment of liver disease, containing alum or ammonium aluminum sulfate and white egg or individual. The composition of claim 1 wherein the alum or ammonium aluminum sulfate is commercially available or processed or specially treated. The composition of claim 1, wherein the liver disease is hepatitis, cirrhosis and liver cancer due to hepatitis B virus. According to claim 1, wherein the composition comprising 0.01 to 80% by weight of the combination drug. A dietary supplement comprising a complex herbal medicine containing alum or ammonium aluminum sulfate having a liver disease prevention effect and a white egg or a dog, and a food-acceptable food supplement additive.